Wall Street Zen upgraded shares of Entera Bio (NASDAQ:ENTX – Free Report) from a strong sell rating to a sell rating in a report released on Saturday,Wall Street Zen reports.
A number of other research analysts have also weighed in on ENTX. Cantor Fitzgerald started coverage on Entera Bio in a research note on Tuesday, September 22nd. They set an “overweight” rating on the stock. UBS Group set a $9.00 price objective on Entera Bio in a research report on Friday, September 18th. Guggenheim assumed coverage on Entera Bio in a research note on Thursday, September 24th. They issued a “buy” rating and a $11.00 target price for the company. Leerink Partners started coverage on shares of Entera Bio in a research report on Friday, September 18th. They set an “outperform” rating and a $9.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Entera Bio in a research note on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $9.60.
View Our Latest Report on ENTX
Entera Bio Price Performance
Shares of ENTX opened at $3.31 on Friday. Entera Bio has a 1-year low of $0.91 and a 1-year high of $4.20. The stock has a market cap of $576.40 million, a price-to-earnings ratio of -8.49 and a beta of 1.48. The firm has a 50 day simple moving average of $2.93 and a 200-day simple moving average of $2.03.
Entera Bio (NASDAQ:ENTX – Get Free Report) last issued its quarterly earnings data on Friday, November 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.05). On average, equities analysts expect that Entera Bio will post -0.40 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC increased its holdings in Entera Bio by 338.4% during the 1st quarter. Renaissance Technologies LLC now owns 473,442 shares of the company’s stock worth $526,000 after purchasing an additional 365,441 shares during the last quarter. Seven Fleet Capital Management LP raised its position in shares of Entera Bio by 51.9% in the 1st quarter. Seven Fleet Capital Management LP now owns 205,542 shares of the company’s stock valued at $228,000 after purchasing an additional 70,224 shares in the last quarter. Logos Global Management LP purchased a new position in shares of Entera Bio during the 3rd quarter valued at approximately $12,838,000. RA Capital Management L.P. purchased a new position in shares of Entera Bio during the 3rd quarter valued at approximately $14,265,000. Finally, Marshall Wace LLP acquired a new stake in shares of Entera Bio during the third quarter worth approximately $613,000. 14.11% of the stock is owned by institutional investors and hedge funds.
About Entera Bio
Entera Bio Ltd. is a clinical-stage biopharmaceutical company based in Jerusalem, Israel. It develops oral peptide therapies for conditions that have traditionally been treated with injectable medicines, with a focus on bone and endocrine disorders. The company’s development programs include EB613, an oral formulation of parathyroid hormone being studied for osteoporosis, and EB612, an oral parathyroid hormone candidate for hypoparathyroidism. Entera uses its proprietary oral-delivery technology to pursue the development of these therapies.
Recommended Stories
- Five stocks we like better than Entera Bio
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.
